Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 1 patents
4 readers on Mendeley
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI114885

Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin.

R D Christen, D K Hom, D C Porter, P A Andrews, C L MacLeod, L Hafstrom, and S B Howell

Department of Medicine, University of California, San Diego, La Jolla 92093.

Find articles by Christen, R. in: JCI | PubMed | Google Scholar

Department of Medicine, University of California, San Diego, La Jolla 92093.

Find articles by Hom, D. in: JCI | PubMed | Google Scholar

Department of Medicine, University of California, San Diego, La Jolla 92093.

Find articles by Porter, D. in: JCI | PubMed | Google Scholar

Department of Medicine, University of California, San Diego, La Jolla 92093.

Find articles by Andrews, P. in: JCI | PubMed | Google Scholar

Department of Medicine, University of California, San Diego, La Jolla 92093.

Find articles by MacLeod, C. in: JCI | PubMed | Google Scholar

Department of Medicine, University of California, San Diego, La Jolla 92093.

Find articles by Hafstrom, L. in: JCI | PubMed | Google Scholar

Department of Medicine, University of California, San Diego, La Jolla 92093.

Find articles by Howell, S. in: JCI | PubMed | Google Scholar

Published November 1, 1990 - More info

Published in Volume 86, Issue 5 on November 1, 1990
J Clin Invest. 1990;86(5):1632–1640. https://doi.org/10.1172/JCI114885.
© 1990 The American Society for Clinical Investigation
Published November 1, 1990 - Version history
View PDF
Abstract

Cisplatin (DDP) is the most effective drug for the treatment of human ovarian cancer, but the mechanisms that determine sensitivity to the cytotoxic action of DDP are not well understood. Treatment of two human ovarian carcinoma cell lines with epidermal growth factor (EGF) simultaneously increased sensitivity to DDP and caused a persistent change in morphology in the absence of any mitogenic effect. Sensitization to DDP was shown to be dependent on both EGF concentration and EGF receptor number in C127 mouse fibroblasts expressing the human EGF receptor after transfection with a pBPV plasmid construct containing the human EGF receptor gene under control of the transferrin receptor 3'-inducible regulator. Sensitization of human ovarian carcinoma cells to DDP was not blocked by inhibition of protein synthesis. EGF did not enhance sensitivity to DDP or alter morphology in DDP-resistant human ovarian carcinoma cells despite the presence of functional EGF receptors on these cells. These results showed that elements of the signal transduction pathway activated by EGF determined cellular sensitivity to DDP, and that a DDP-resistant phenotype is associated with a defect in this signal transduction pathway.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1632
page 1632
icon of scanned page 1633
page 1633
icon of scanned page 1634
page 1634
icon of scanned page 1635
page 1635
icon of scanned page 1636
page 1636
icon of scanned page 1637
page 1637
icon of scanned page 1638
page 1638
icon of scanned page 1639
page 1639
icon of scanned page 1640
page 1640
Version history
  • Version 1 (November 1, 1990): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 patents
4 readers on Mendeley
See more details